HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

CYP24A1 as a potential target for cancer therapy.

Abstract
Increasing evidence has accumulated to suggest that vitamin D may reduce the risk of cancer through its biologically active metabolite, 1α,25(OH)2D3, which inhibits proliferation and angiogenesis, induces differentiation and apoptosis, and regulates many other cellular functions. Thus, it is plausible to assume that rapid clearance of 1α,25(OH)2D3 by highly expressed CYP24A1 could interrupt the normal physiology of cells and might be one cause of cancer initiation and progression. In fact, enhancement of CYP24A1 expression has been reported in literature for many cancers. Based on these findings, CYP24A1-specific inhibitors and vitamin D analogs which are resistant to CYP24A1-dependent catabolism might be useful for cancer treatment. CYP24A1-specific inhibitor VID400, which is an azole compound, markedly enhanced and prolonged the antiproliferative activity of 1α,25(OH)2D3 in the human keratinocytes. Likewise, CYP24A1-resistant analogs such as 2α-(3-hydroxypropoxy)-1α,25(OH)2D3 (O2C3) and its C2-epimer ED-71 (Eldecalcitol), and 19nor- 2α-(3-hydroxypropyl)-1α,25(OH)2D3 (MART-10) showed potent biological effects. Our in vivo studies using rats revealed that MART-10 had a low calcemic effect, which is a suitable property as an anticancer drug. Much lower affinity of MART-10 for vitamin D binding protein (DBP) as compared with 1α,25(OH)2D3 may be related to its more potent cellular activities. Based on these results, we conclude that (1) high affinity for VDR, (2) resistance to CYP24A1-dependent catabolism, (3) low affinity for DBP, and (4) low calcemic effect may be required for designing potent vitamin D analogs for cancer treatment.
AuthorsToshiyuki Sakaki, Kaori Yasuda, Atsushi Kittaka, Keiko Yamamoto, Tai C Chen
JournalAnti-cancer agents in medicinal chemistry (Anticancer Agents Med Chem) Vol. 14 Issue 1 Pg. 97-108 (Jan 2014) ISSN: 1875-5992 [Electronic] Netherlands
PMID23869781 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Review)
Chemical References
  • Antineoplastic Agents
  • Enzyme Inhibitors
  • Cholecalciferol
  • Steroid Hydroxylases
  • CYP24A1 protein, human
  • Cyp24a1 protein, rat
  • Vitamin D3 24-Hydroxylase
Topics
  • Animals
  • Antineoplastic Agents (chemistry, therapeutic use)
  • Cholecalciferol (analogs & derivatives, metabolism, therapeutic use)
  • Enzyme Inhibitors (chemistry, therapeutic use)
  • Humans
  • Metabolic Networks and Pathways
  • Molecular Targeted Therapy
  • Neoplasms (drug therapy, metabolism)
  • Protein Conformation
  • Steroid Hydroxylases (antagonists & inhibitors, chemistry, metabolism)
  • Vitamin D3 24-Hydroxylase

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: